Accessibility help Search NICE… Sign in NICE Pathways NICE guidance Life sciences Standards and indicators Evidence search BNF British National Formulary British National Formulary BNFC British National Formulary for Children British National Formulary for Children CKS Clinical Knowledge Summaries Clinical Knowledge Summaries Journals and databases Read about our approach to COVID-19 Guidance Evidence-based recommendations developed by independent committees, including professionals and lay members, and consulted on by stakeholders. View all guidance Conditions and diseases Health and social care delivery Health protection Lifestyle and wellbeing Population groups Settings Get involved We want you to be involved in our work. Tell us what matters to you, your organisation or your community. There are many ways you can get involved as a healthcare professional or a member of the public. Register as a stakeholder. Comment on a consultation. Join a committee. Come to a meeting. Come to an event. About us Find out more about who we are what we do and how we support social care life sciences the public international health organisations. The NICE strategy 2021 to 2026 sets out an ambitious vision for our future. Read our NICE impact report on people with a learning disability Request a speaker for your live or virtual event Join the insight community to help us improve Latest news Over 600 people set to benefit from innovative lung cancer treatment within the Cancer Drugs Fund More than 600 people could benefit from an innovative drug for a form of lung cancer as NICE publishes final draft guidance recommending osimertinib within the Cancer Drugs Fund. NICE creates new menu of treatment options for those suffering from depression People with depression should make the choice on what treatment option is right for them, in discussion with their healthcare professional, NICE says in new draft guidance. NICE draft guidance recommends new treatment for spinal muscular atrophy as part of a managed access agreement Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit from a new treatment after NICE today (19 November 2021) published draft guidance recommending risdiplam (also called Evrysdi and made by Roche) as part of a managed access agreement (MAA). NICE approves first long-acting injectable HIV-1 treatment NICE has today (18 November 2021) published draft guidance recommending the first long-acting injectable treatment for HIV-1 infection in adults. Explore NICE Into practice Resources to help you use our guidance and quality standards Financial planning Advice and tools to help you make the best use of your resources Antimicrobial resistance View our antimicrobial prescribing guidelines Our role in patient safety Our guidelines make evidence-based, best practice recommendations. Find journals and databases Access to a range of journals and other evidence-based resources. NICE Pathways NICE guidance Life sciences Standards and indicators Evidence search BNF British National Formulary British National Formulary BNFC British National Formulary for Children British National Formulary for Children CKS Clinical Knowledge Summaries Clinical Knowledge Summaries Journals and databases About NICE Into practice Get involved with NICE Jobs News Newsletters and alerts Contact us Leave feedback Reusing our content NICE UK Open Content Licence Syndicate our content Facebook Twitter YouTube Instagram LinkedIn Accessibility Freedom of information Glossary Terms and conditions Privacy notice Cookies © NICE 2021. All rights reserved. Subject to Notice of rights. Cookies on the NICE website and services Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit. For more information, view our cookie statement. (Opens in a new window) Accept all cookiesReject cookies Essential cookies These cookies enable basic functions like page navigation and access to secure areas of the website. Our website cannot function properly without these cookies and they can only be deactivated by changing your browser preferences. Preference cookies These cookies remember information that changes the way our website behaves or looks, like your preferred layout or previously viewed pages. Preference cookies On Off Website usage cookies We use tools such as Google Analytics, Hotjar, Google Optimize and Loop11 to help us anonymously measure how you use our websites. This allows us to make improvements based on our users' needs. These tools set cookies that store anonymised information about how you got to the site, and how you interact with the site. Show vendors within this category Website usage cookies On Off Marketing and advertising cookies We use Google Ads, LinkedIn, Facebook and Twitter to show adverts on external sites to promote NICE services, events and content. These services may use cookies to help make advertising more effective. These cookies are used for things like showing relevant adverts based on website visits, preventing the same ad from continuously re-appearing, or by measuring how many times people click on these adverts. Show vendors within this category Marketing and advertising cookies On Off